Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

HaemoAdsorption Nach Reanimation An ECMO (HANRAE)

10 augustus 2018 bijgewerkt door: Universitätsklinikum Hamburg-Eppendorf

This study evaluates the use of an additional hemoadsorption device in adult patients undergoing veno-arterial extracorporal membrane oxygenation (ECMO) following cardiac arrest and cardiopulmonary resuscitation in respect to its effects on post resuscitation inflammatory syndrome.

At implantation of the ECMO the participants are going to be randomized into a treatment and a control group. The first will be outfitted with a polymer-based adsorption device implemented in the extracorporal circulation established by ECMO for 48h, the control group is going to be treated by ECMO and standard intensive care alone. To detect any significant differences in terms of inflammatory response and patient outcome the investigators will regularly determine the blood levels of certain cytokines in fixed intervalls. In addition, the investigators are going to compare secondary clinical outcome parameters like organ disfunction and 30d mortality.

Studie Overzicht

Toestand

Onbekend

Interventie / Behandeling

Gedetailleerde beschrijving

Even after successful return of spontaneus circulation (ROSC), patients suffering a cardiac arrest with subsequent cardipulmonary resuscitation (CPR) are still facing a significant morbidity and mortality in the post-resuscitation phase. They are nowadays often subjected to extracorporal membrane oxygenation (ECMO), supplementing or even replacing cardiac and/or pulmonary function for a certain period in order to reduce the workload for these critical organs. However, as well as the initial ischemia/reperfusion damage, subsequent procedures create significant stress to the patients organism, causing severe inflammation and contributing to post-resuscitation single or multiple organ disfunction and/or failure.

Continously eliminating relevant mediators of inflammation by adsorption to a polymer-based material in extracorporal circulation has been shown to influence the course of this inflammatory syndrome in patients with severe infection and sepsis. Any relevant clinical studies evaluating the use of such a device in post-resuscitation care are still lacking, yet.

Therefore, in this study the investigators are going to test the hypothesis that such a device is capable of significantly altering the cytokine levels during and even shortly after a 48h treatment period in addition to the standard ECMO therapy all patients are going to receive. As a secondary outlook, the investigators are going to compare the clinical outcome of the patients in terms of major organ disfunction and overall 30d mortality.

At the time extracoporal circulation is established during or after CPR, all participants (n=40) are enrolled and randomized into a treatment and a control group. The extracorporal circulation over the ECMO device is then outfitted with a certified in line adsorption cartridge for the treatment group. Due to technical reasons, this cartridge has to be exchanged for another identical module after 24h of continuous treatment. Adsorption therapy is terminated after 48h. The control group is subjected to ECMO without any additional modules. Both groups are receiving standard intensive care during the course of the study. All diagnostic and therapeutic decisions with the exemption of those directly concerning the hemoadsorption and sampling protocol are at sole discretion of the clinical staff.

For both groups, blood samples are taken at time points 0,6,12,24,36,48,72h after establishment of ECMO or time of death, respectively. Relevant parameters are then determined in different diagnostic and research laboratories with/without sample preprocessing by the study personal in accordance with preanalytic requirements. All relevant clinical data is extracted from the digital patient data management system (PDMS).

Studietype

Ingrijpend

Inschrijving (Verwacht)

40

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Hamburg, Duitsland, 20246
        • Werving
        • University Hospital Hamburg-Eppendorf
        • Contact:
          • Jens Kubitz, Prof. Dr.
          • Telefoonnummer: +49 (0) 40 7410 - 52415
          • E-mail: j.kubitz@uke.de
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 75 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

All patients receiving a veno-arterial ECMO after cardiac arrest at the study site are eligible for the study. Thus, the criteria are defined by the SOP "ECMO bei Reanimation" of the University Heart Center Hamburg:

Inclusion Criteria:

  • observed cardiac arrest with initial hyperdynamic rhythm and sufficient primary resuscitation

Exclusion Criteria (absolute):

  • existing "do-not-resuscitate"-order from the patient/a priori palliative situation
  • severe trauma
  • severe acute bleeding due to any cause
  • confirmed or highly likely relevant and severe persistent neurologic impairment
  • severe limiting comorbidities with independent and relevant reduction of life expectancy (e.g. malignoma, preexistent heart failure syndrome, obstructive/restrictive lung disease, hepatic cirrhosis)

Exclusion Criteria (relative, at the discretion of the responsible provider):

  • severe initial lacacidosis
  • prolongued mechanical resuscitation (>30min)

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Treatment
Inclusion of an extracorporal in line adsorbing cartridge for 48h (with a cartridge exchange at 24h) post establishing ECMO in addition to standard post resuscitation intensive care
see arm description
Geen tussenkomst: Control
ECMO and standard post resuscitation intensive care without any additional module in extracorporal circulation

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
IL-6 at hour 6
Tijdsspanne: 6 hours post establishment of extracorporal membrane oxygenation (ECMO)
Blood levels of interleukine 6 will be compared between intervention and control group
6 hours post establishment of extracorporal membrane oxygenation (ECMO)
IL-6 at hour 12
Tijdsspanne: 12 hours post establishment of extracorporal membrane oxygenation (ECMO)
Blood levels of interleukine 6 will be compared between intervention and control group
12 hours post establishment of extracorporal membrane oxygenation (ECMO)
IL-6 at hour 24
Tijdsspanne: 24 hours post establishment of extracorporal membrane oxygenation (ECMO)
Blood levels of interleukine 6 will be compared between intervention and control group
24 hours post establishment of extracorporal membrane oxygenation (ECMO)
IL-6 at hour 48
Tijdsspanne: 48 hours post establishment of extracorporal membrane oxygenation (ECMO)
Blood levels of interleukine 6 will be compared between intervention and control group
48 hours post establishment of extracorporal membrane oxygenation (ECMO)
IL-6 at hour 72
Tijdsspanne: 72 hours post establishment of extracorporal membrane oxygenation (ECMO)
Blood levels of interleukine 6 will be compared between intervention and control group
72 hours post establishment of extracorporal membrane oxygenation (ECMO)
TNF-a at hour 6
Tijdsspanne: 6 hours post establishment of extracorporal membrane oxygenation (ECMO)
Blood levels of human tumor necrosis factor alpha will be compared between intervention and control group
6 hours post establishment of extracorporal membrane oxygenation (ECMO)
TNF-a at hour 12
Tijdsspanne: 12 hours post establishment of extracorporal membrane oxygenation (ECMO)
Blood levels of human tumor necrosis factor alpha will be compared between intervention and control group
12 hours post establishment of extracorporal membrane oxygenation (ECMO)
TNF-a at hour 24
Tijdsspanne: 24 hours post establishment of extracorporal membrane oxygenation (ECMO)
Blood levels of human tumor necrosis factor alpha will be compared between intervention and control group
24 hours post establishment of extracorporal membrane oxygenation (ECMO)
TNF-a at hour 48
Tijdsspanne: 48 hours post establishment of extracorporal membrane oxygenation (ECMO)
Blood levels of human tumor necrosis factor alpha will be compared between intervention and control group
48 hours post establishment of extracorporal membrane oxygenation (ECMO)
TNF-a at hour 72
Tijdsspanne: 72 hours post establishment of extracorporal membrane oxygenation (ECMO)
Blood levels of human tumor necrosis factor alpha will be compared between intervention and control group
72 hours post establishment of extracorporal membrane oxygenation (ECMO)

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
S1P
Tijdsspanne: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Blood levels of sphingosine-1-phosphate will be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
PCT
Tijdsspanne: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The serum levels of procalcitonine will be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
CRP
Tijdsspanne: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The plasma levels of C-related peptide will be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Leukocytes
Tijdsspanne: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The number of leukocytes in simple blood count will be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
BNP
Tijdsspanne: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The serum levels of n-terminal pro brain natriuretic peptide will be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Mean arterial pressure (MAP)
Tijdsspanne: Continuosly from enrollment to 72h post.
The mean arterial pressure as calculated automatically from the invasively measured arterial pressure curve will be compared between intervention and control group.
Continuosly from enrollment to 72h post.
Heart rate (HR)
Tijdsspanne: Continuosly from enrollment to 72h post.
The continuously monitored heart rate will be compared between intervention and control group.
Continuosly from enrollment to 72h post.
Central venous pressure (CVP)
Tijdsspanne: Continuosly from enrollment to 72h post.
The continuously and invasively measured mean central venous pressure will be compared between intervention and control group, if available.
Continuosly from enrollment to 72h post.
haemodynamically relevant medication
Tijdsspanne: Continuosly from enrollment to 72h post.
The continuous intake of the following drugs as chosen by discretion of the clinical staff is extracted from digital PDMS: Norepinephrine, Epinephrine, Dobutamin, inodilatators (Milrinon, Enoximon, Levosimendan)
Continuosly from enrollment to 72h post.
Trop
Tijdsspanne: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The serum levels of troponine T will be compared between intervention and control group
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
CK
Tijdsspanne: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The Plasma levels of creatinkinase will be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Myoglobine
Tijdsspanne: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The Serum levels of myoglobine will be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Hemoglobine
Tijdsspanne: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The total blood concentration of hemoglobine will be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Haptoglobine
Tijdsspanne: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The serum levels of haptoglobine will be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
paO2
Tijdsspanne: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The arterial partial pressure of oxygen as measured by point-of-care blood gas analysis is going to be compared between intervention and control group
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
paCO2
Tijdsspanne: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The arterial partial pressure of carbon dioxide as measured by point-of-care blood gas analysis is going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
SaO2
Tijdsspanne: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The saturation of hemoglobine with oxygen in an arterial blood sample as measured by point-of-care blood gas analysis is going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
SvO2
Tijdsspanne: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The saturation of hemoglobine with oxygen in a central venous blood sample as measured by point-of-care blood gas analysis is going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Horowitz index
Tijdsspanne: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The Horowitz index, calculated as paO2/FiO2 is going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
pH
Tijdsspanne: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The pH of an arterial blood sample is going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
HCO3
Tijdsspanne: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The levels of bicarbonate of an arterial blood sample are going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
BE
Tijdsspanne: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The base excess of an arterial blood sample is going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
N
Tijdsspanne: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The blood levels of sodium are going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
K
Tijdsspanne: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The blood levels of potassium are going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
C
Tijdsspanne: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The blood levels of chloride are going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Lactate
Tijdsspanne: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The blood levels of lactate are going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Mode of Ventilation
Tijdsspanne: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The mode of mechanical ventilation is going to be compared between intervention and control group
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
FiO2
Tijdsspanne: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The inspiratory oxygen fraction at mechanical ventilation is going to be compared between intervention and control group
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Peak inspiratory pressure (pmax)
Tijdsspanne: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The peak inspiratory pressure at mechanical ventilation is going to be compared between intervention and control group
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
PEEP
Tijdsspanne: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The positive end exspiratory pressure at mechanical ventilation is going to be compared between intervention and control group
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Ventilation frequency
Tijdsspanne: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The frequency of mechanical ventilation (cycles/min) is going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Tidal volume
Tijdsspanne: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The tidal volume achieved by mechanical ventilation is going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Total minute ventilation
Tijdsspanne: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The total minute ventilation as measured by the ventilation unit is going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Complicance
Tijdsspanne: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The airway compliance (c) as calculated from ventilator driving pressure(dp=pmax-PEEP) and tidal volume (V): c=V/dp is going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
ASAT
Tijdsspanne: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The plasma levels of asparic acid aminotransferase will be compared between intervention and treatment group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
ALAT
Tijdsspanne: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The plasma levels of alanin aminotransferase will be compared between intervention and treatment group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
INR
Tijdsspanne: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The thrombin time as standardized international normal ratio will be compared between intervention and treatment group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
apTT
Tijdsspanne: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The activated partial thromboplastin time will be compared between intervention and treatment group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Crea
Tijdsspanne: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The plasma creatinine concentration will be compared between intervention and treatment group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
eGFR
Tijdsspanne: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The glomerulary filtration rate, estimated from serum creatinine by the CKP-EPI formula will be compared between intervention and treatment group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Volume status
Tijdsspanne: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
For a clinical estimation of the renal function, the following parameters are extracted from the digital PDMS: Fluid intake, diuresis, additional loss of body fluids (e.g. gastral reflux, vomitting, extraction by kidney replacement therapy)
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
NSE
Tijdsspanne: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The serum levels of neuron specific enolase will be compared between intervention and treatment group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Mortality
Tijdsspanne: 30 days post enrollment
Mortality within 30 days after enrollment due to any cause will be determined, if follow up is technically feasible
30 days post enrollment

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Jens Kubitz, Prof. Dr., Universitätsklinikum Hamburg-Eppendorf

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Verwacht)

1 oktober 2018

Primaire voltooiing (Verwacht)

1 mei 2019

Studie voltooiing (Verwacht)

1 september 2019

Studieregistratiedata

Eerst ingediend

3 mei 2018

Eerst ingediend dat voldeed aan de QC-criteria

10 augustus 2018

Eerst geplaatst (Werkelijk)

16 augustus 2018

Updates van studierecords

Laatste update geplaatst (Werkelijk)

16 augustus 2018

Laatste update ingediend die voldeed aan QC-criteria

10 augustus 2018

Laatst geverifieerd

1 augustus 2018

Meer informatie

Termen gerelateerd aan deze studie

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • UKEHANRAE

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Ja

product vervaardigd in en geëxporteerd uit de V.S.

Ja

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren